Titlebook: Renal Cell Carcinoma; Molecular Targets an Ronald M. Bukowski,Robert A. Figlin,Robert J. Motz Book 2015Latest edition Springer Science+Busi

RAG

臆断

Anti-VEGF and VEGFR Monoclonal Antibodies in RCC,women [.]. Its management has undergone a transformation in the past few years: novel targeted therapies have expanded considerably for patients with metastatic renal cell carcinoma (mRCC). Previously, systemic treatment was limited to cytokine therapy with interleukin (IL)-2 or interferon (IFN)-alp